• Have a question?
    Open from 8am to 7pm Monday to Friday    Call customer services
    0345 54 32 600


| Print

Novo-Nordisk A/S (NVO)

ADR
Sell: $46.68|Buy: $46.77|Change: 0.60 (1.30%)

Open 

$46.35

Previous close 

$46.14

Trade high 

$47.165

Volume 

10,865,450

Year high 

$64.16

Year low 

$35.12

Dividend yield 

3.89%

Market capitalisation 

$206.69 bn

P/E ratio 

11.35

ISIN 

US6701002056

This share can be held in a Dealing accountStocks and shares ISALifetime ISAJISASIPP

Share price

Dividends

PreviousLatest
Record date30/03/202617/08/2026
Ex-dividend date30/03/202617/08/2026
Payment date08/04/202625/08/2026
Amount$1.21738$0.57919

Performance 21/08/2026

1D | 1M | 3M | 1Y | 3Y ann | 5Y ann | 10Y ann

Total return (%)
Novo-Nordisk A/S+ 1.30
More...

Company profile

With roughly one-third of the global branded diabetes treatment market, Novo Nordisk is the world's leading provider of diabetes care products. Based in Denmark, the company manufactures and markets a variety of human and modern insulins for patients with diabetes, as well as injectable and oral GLP-1 therapies, across its obesity and diabetes care segment. Novo also has a rare disease segment (contributing less than 10% of revenue) that specializes in protein therapies for hemophilia and other disorders.

Sector 

Healthcare

AJ Bell Management Limited (company number 03948391), AJ Bell Securities Limited (company number 02723420) and AJ Bell Asset Management Limited (company number 09742568) are authorised and regulated by the Financial Conduct Authority. All companies are registered in England and Wales at 4 Exchange Quay, Salford Quays, Manchester M5 3EE. See website for full details. AJ Bell procures the provision of the Morningstar Licensed Tools on an “as is” basis and does not guarantee the performance of or accept liability for the Licensed Tools. To the maximum extent permitted by law, AJ Bell excludes liability for the Licensed Tools, including liability for any failure, interruption, delay or defect in the performance of any Licensed Tool, unless it arises as a direct result of the negligence of AJ Bell.

© Copyright 2026 AJ Bell. All rights reserved.